iss 1018 cpg oligodeoxynucleotide
iss 1018 cpg oligodeoxynucleotide: developed by 1 company · 2 clinical trials tracked.
iss 1018 cpg oligodeoxynucleotide evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could iss 1018 cpg oligodeoxynucleotide → DVAX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| DYNAVAX TECHNOLOGIES CORP (DVAX) Shingles | Approved |
Clinical Trials (2)
A Phase 1 Double-blind, Randomized, Dose Finding Clinical Trial With an Open-label run-in Part to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years
Primary endpoint: Solicited Adverse Events
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Aalum Adjuvants and VRC HIV Env Trimer 4571 and 3M-052-AF With Alum in Healthy, HIV-uninfected Adults
Primary endpoint: Number of Participants Reporting Local Solicited Adverse Events Signs and Symptoms: Pain and/or Tenderness
Frequently asked questions
Who is developing iss 1018 cpg oligodeoxynucleotide?
iss 1018 cpg oligodeoxynucleotide is being developed by DYNAVAX TECHNOLOGIES CORP.
How many clinical trials involve iss 1018 cpg oligodeoxynucleotide?
BioSniper tracks 2 clinical trials involving iss 1018 cpg oligodeoxynucleotide.